5.Conclusion
Our results demonstrated that elevated serum sCD25 at diagnosis in pediatric LCH patients was associated with high-risk clinical features and worse prognosis. The data revealed that levels of sCD25 at baseline had predictive value for progression/recurrence of LCH after treatment with first-line chemotherapy. These findings call for prospective, independent validation in larger patient cohorts to confirm the predictive utility and better define the potential clinical utility. Exploration of such inflammatory biomarkers is valuable in elucidating the role of inflammation in LCH disease pathogenesis and progression, further refining clinical stratification and developing new therapeutic targets.